Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients

被引：10

作者：

Kumarasamy, Nagalingeswaran ^{[1
]}

Prabhu, Sandeep ^{[2
]}

Chandrasekaran, Ezhilarasi ^{[1
]}

Poongulali, Selvamuthu ^{[1
]}

Pradeep, Amrose ^{[1
]}

Chitra, Devaraj ^{[1
]}

Balakrishnan, Ramasamy ^{[1
]}

Benson, Constance A. ^{[3
]}

机构：

[1] Voluntary Hlth Serv Chennai, YRGCARE Med Ctr, Chennai, Tamil Nadu, India

[2] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA

[3] Univ Calif San Diego, Dept Infect Dis, San Diego, CA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2019年 / 68卷 / 06期

关键词：

HIV; dolutegravir; safety; efficacy; resource-limited setting;

D O I：

10.1093/cid/ciy763

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this first study of generic dolutegravir (DTG)-containing regimens in a low-resource setting, we assessed safety, tolerability, and efficacy within a prospective cohort of 564 patients with at least 6 months of clinical follow-up. We provide support for a large-scale transition to DTG as part of first-line regimens.

引用

页码：1048 / 1051

页数：4

共 14 条

[1] [Anonymous], 2018, POT SAF ISS AFF WOM
[2] Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
Behrens, G
Dejam, A
Schmidt, H
Balks, HJ
Brabant, G
Körner, T
Stoll, M
Schmidt, RE
[J]. AIDS, 1999, 13 (10) : F63 - F70
[3] Cecelia AJ, 2006, NATL MED J INDIA, V19, P14
[4] Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects
Dooley, Kelly E.
Sayre, Patrick
Borland, Julie
Purdy, Elizabeth
Chen, Shuguang
Song, Ivy
Peppercorn, Amanda
Everts, Stephanie
Piscitelli, Stephen
Flexner, Charles
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (01) : 21 - 27
[5] Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
Hoffmann, C.
Welz, T.
Sabranski, M.
Kolb, M.
Wolf, E.
Stellbrink, H-J
Wyen, C.
[J]. HIV MEDICINE, 2017, 18 (01) : 56 - 63
[6] Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV
Kandel, Christopher E.
Walmsley, Sharon L.
[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3547 - 3555
[7] Kumarasamy N, 2018, J VIRUS ERAD, V4, P37
[8] Levin J., 2017, SUPERIOR EFFICACY DO
[9] Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients
Ma, Qing
Vaida, Florin
Wong, Jenna
Sanders, Chelsea A.
Kao, Yu-ting
Croteau, David
Clifford, David B.
Collier, Ann C.
Gelman, Benjamin B.
Marra, Christina M.
McArthur, Justin C.
Morgello, Susan
Simpson, David M.
Heaton, Robert K.
Grant, Igor
Letendre, Scott L.
[J]. JOURNAL OF NEUROVIROLOGY, 2016, 22 (02) : 170 - 178
[10] Meireles MV, 2018, AIDS 2018 JUL 23 27

← 1 2 →